EUVIMEDEUVIMED entdecken
Crossref

Cost‐Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step‐Up Treatment of Childhood Asthma

Jefferson Antonio Buendía iD, Juan Antonio Buendia Sánchez

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Jefferson Antonio Buendía und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Med…. Hauptthemen laut MEDLINE: Asthma, Androstadienes, Albuterol, Bronchodilator Agents. Die Arbeit nennt 25 Literaturangaben. Gefördert von: The authors received no specific funding for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In children aged 6–11 years who have not responded to daily low‐dose inhaled corticosteroids, it is recommended to increase ICS to a medium dose plus as‐needed SABA reliever, or to change to combination low‐dose ICS‐LABA plus as‐needed SABA relief. Recently, fluticasone propionate and salmeterol (FSC) have been shown to be more effective than fluticasone propionate alone in preventing exacerbations in patients with eosinophilic asthma. This study aims to evaluate the cost‐utility of FSC versus medium doses of FP alone in Colombian patients who do not respond to low‐dose inhaled corticosteroids. Materials and Methods A probabilistic Markov model was created to estimate the cost and quality‐adjusted life‐years (QALYs) of patients with severe asthma in Colombia. Cost‐effectiveness was evaluated at a willingness‐to‐pay (WTP) value of US$5180. This analysis used quality‐adjusted life years (QALYs) and costs from a third‐payer perspective over a 5‐year time horizon.

Results

FSC incurs a higher cost than FP alone, with a mean incremental cost of USD 273; it provides a marginal improvement in quality‐adjusted life years (QALYs) of 0.06, yielding an incremental cost‐utility ratio (ICUR) of USD 4806 per QALY gained. These results imply that FSC might be a cost‐effective alternative at a willingness‐to‐pay (WTP) threshold of USD 5180.

Conclusion

This study's findings are aligned with previous evidence on the economic value of ICS/LABA combinations, which found similar cost‐effectiveness ratios for ICS/LABA therapies within accepted thresholds. Our probabilistic perspective supports FSC's potential as a feasible option in clinical practice for achieving better asthma control in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAndrostadienesAlbuterolBronchodilator AgentsAnti-Asthmatic AgentsHumansChildCost-Benefit AnalysisQuality-Adjusted Life YearsFluticasoneMarkov ChainsColombiaSalmeterol XinafoateDrug CombinationsDrug Therapy, CombinationMaleFemaleFluticasone-Salmeterol Drug Combination

Stichwörter der Autor:innen

asthmacolombiacostfluticasonesalmeterol

Substanzen

FluticasoneAndrostadienesAlbuterolSalmeterol XinafoateDrug CombinationsBronchodilator AgentsAnti-Asthmatic AgentsFluticasone-Salmeterol Drug Combination

Autor:innen und Institutionen

  • Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia.

ORCID-Profile: Jefferson Antonio Buendía

Förderung

  • The authors received no specific funding for this study.

Zitieren

APA

Buendía, J. A., & Buendia Sánchez, J. A. (2025). Cost‐Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step‐Up Treatment of Childhood Asthma. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71244

Vancouver

Buendía JA, Buendia Sánchez JA. Cost‐Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step‐Up Treatment of Childhood Asthma. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71244

BibTeX
@article{Buenda2025,
  author = {Buendía, Jefferson Antonio and Buendia Sánchez, Juan Antonio},
  title = {Cost‐Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step‐Up Treatment of Childhood Asthma},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71244}
}
Kostenlos starten →